Literature DB >> 2172117

Rapid dysplastic transformation of human genital cells by human papillomavirus type 18.

W Barnes1, G Woodworth, S Waggoner, M Stoler, A B Jenson, G Delgado, J DiPaolo.   

Abstract

This study delineates differences in biologic activity between human papillomavirus (HPV) types 16 and 18. Human cervical and foreskin epithelial cells were cultured and transfected with recombinant HPV-16 and -18 DNA, resulting in immortalized cell lines. Normal epithelial cells as well as HPV-16 and -18 immortalized cells of both early passages (less than 40 population doublings) and late passages (greater than 180 population doublings) were transplanted in athymic mice. Normal squamous cells formed well-stratified epithelium, while HPV immortalized cells developed either normal-appearing epithelium or typical dysplastic changes. Dysplastic changes were seen in none of the 13 grafts with early-passage HPV-16 cell lines, while 9 of 14 grafts with early-passage HPV-18 cell lines developed dysplasias (P less than 0.0004). These results support previous clinical observations suggesting that HPV-18 may be associated with a more aggressive and rapidly progressive form of cervical neoplasia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172117     DOI: 10.1016/0090-8258(90)90070-2

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer.

Authors:  M F Baay; J Koudstaal; H Hollema; J M Duk; M P Burger; W G Quint; E Stolz; P Herbrink
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

2.  Nucleolin as activator of human papillomavirus type 18 oncogene transcription in cervical cancer.

Authors:  Edgar Grinstein; Peter Wernet; Peter J F Snijders; Frank Rösl; Inge Weinert; Wentao Jia; Regine Kraft; Christiane Schewe; Michael Schwabe; Steffen Hauptmann; Manfred Dietel; Chris J L M Meijer; Hans-Dieter Royer
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.